Recordati

Historical price data

Founded in 1926, Recordati has grown from a local Italian pharmacy into a global pharmaceutical force with a market valuation of approximately $9.9 billion. The company's strategy is built on a dual therapeutic focus—addressing widespread common diseases and high-need rare diseases—supported by a fully integrated value chain from R&D to manufacturing and global commercialization. With a presence in 150 countries, a robust pipeline, and a seasoned leadership team, Recordati is positioned for sustained growth as it celebrates its centennial and looks to the next century of innovation.

Fully integrated pharmaceutical value chain encompassing in-house R&D, chemical and finished product manufacturing at nine global sites, and a worldwide commercialization network in approximately 150 countries.

Recordati competes in a segmented market: against large pharma and biotechs in rare diseases, and against both large pharma and generics in specialty/primary care. Its integrated model and focused commercial expertise in niche endocrine diseases provide a defensible competitive position.